LEXINGTON, Mass.--(BUSINESS WIRE)--May 4, 2006--Critical Therapeutics, Inc. (Nasdaq: CRTX - News), a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases, today reported financial results for the quarter ended March 31, 2006. The Company also announced that it is undertaking a comprehensive review of its cost structure to reduce expenses for 2006 and 2007. These reductions should provide additional capital to support the anticipated 2007 launch of the controlled-release (CR) formulation of zileuton.
